Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma

PURPOSE: Enhancer of zeste homolog 2 (EZH2), a chromatin remodeler, is implicated in the pathogenesis of clear cell renal cell carcinoma (ccRCC). However, the effect of EZH2 on outcomes in localized ccRCC is unclear, and molecular biomarkers are not currently integrated into prognostic models or adj...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Thai Huu, Kapur, Payal, Eckel-Passow, Jeanette E., Christie, Alana, Joseph, Richard W., Serie, Daniel J., Cheville, John C., Thompson, R. Houston, Homayoun, Farrah, Panwar, Vandana, Brugarolas, James, Parker, Alexander S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678341/
https://www.ncbi.nlm.nih.gov/pubmed/28976794
http://dx.doi.org/10.1200/JCO.2017.73.3238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678341/
https://www.ncbi.nlm.nih.gov/pubmed/28976794
http://dx.doi.org/10.1200/JCO.2017.73.3238

Ejemplares similares